Labeling Error Prompts 28,000-Bottle Recall of Abbvie’s Thyroid Drug

January 18, 2013

Abbvie, the new biopharma spinoff from Abbott Laboratories, is recalling more than 28,000 bottles of its thyroid drug Synthroid due to a labeling error that could result in patients taking the wrong dose.

The affected lot’s labels states the bottles contain 150-mcg tablets when in fact they contain 75-mcg tablets. The problem was first identified by a customer, Abbvie spokesman Greg Miley said Monday. The Chicago-based company is not aware of an increase in patient complaints or adverse events from the affected lot of Synthroid (levothyroxine sodium), Miley added.

The hard fact is, you can’t be on the manufacturing floor, in the labs or control rooms where people face the decisions that will test their training. But you can give them the reinforcement they need to make the right decisions with FDAnews’ six-lesson DVD employee training package Focus on GxPs: A DVD Training Toolkit for Your Most Common and Costly Manufacturing Mistakes.

This six-disc package includes six modules, along with leader discussion guides, illustrating six of the most common mistakes that lead to ruined batches, recalls or worse. Each 10- to 12-minute scenario shows how and why human errors occur, and reinforces the proper way to handle each situation. Don’t miss your opportunity, order your copy today!